Use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases: A focus on inflammatory bowel diseases and mucositis

Frontiers in Microbiology

Volumn 8, Issue MAY, 2017, Pages

  Carvalho, Rodrigo D De Oliveira ^a   do Carmo, Fillipe L R ^a   Junior, Alberto de Oliveira ^a   Langella, Philippe ^b   Chatel, Jean Marc ^b   Bermúdez Humarán, Luis G ^b   Azevedo, Vasco ^a   de Azevedo, Marcela S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Genetic engineering; Inflammatory bowel diseases; Lactic acid bacteria; Lactococcus lactis; Mucositis

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 8; MUCIN 2; PANCREATITIS ASSOCIATED PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN ZO1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; BIFIDOBACTERIUM; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DYSBIOSIS; ENTERITIS; FECES ANALYSIS; GENE; GENE EXPRESSION SYSTEM; GRAM POSITIVE BACTERIUM; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOCOCCUS LACTIS; MICROBIAL COMMUNITY; MUCOSA INFLAMMATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; STREPTOCOCCUS; TRANSCRIPTIONAL REPRESSOR GENE; ULCERATIVE COLITIS;

EID: 85019703564     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.00800     Document Type: Review

References (138)

1. Adolfsson, O., Meydani, S. N., and Russell, R. M. (2004). Yogurt and gut function. Am. J. Clin. Nutr. 80, 245-256.
2. Ananthakrishnan, A. N. (2015). Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 12, 205-217. doi: 10.1038/nrgastro.2015.34
3. Anderson, R. C., Cookson, A. L., McNabb, W. C., Park, Z., McCann, M. J., Kelly, W. J., et al. (2010). Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 10:316. doi: 10.1186/1471-2180-10-316
4. Antin, J. H., Weisdorf, D., Neuberg, D., Nicklow, R., Clouthier, S., Lee, S. J., et al. (2002). Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100, 3479-3482. doi: 10.1182/blood-2002-03-0985
5. Antunes, M. M., Leocádio, P. C. L., Teixeira, L. G., Leonel, A. J., Cara, D. C., Menezes, G. B., et al. (2016). Pretreatment with L-citrulline positively affects the mucosal architecture and permeability of the small intestine in a murine mucositis model. J. Parenter. Enteral. Nutr. 40, 279-286. doi: 10.1177/0148607114567508
6. Bahey-El-Din, M., Gahan, C. G., and Griffin, B. T. (2010). Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr. Gene Ther. 10, 34-45. doi: 10.2174/156652310790945557
7. Bajaj, B. K., Claes, I. J. J., and Lebeer, S. (2015). Functional mechanisms of probiotics. J. Microbiol. Biotechnol. Food Sci. 4, 321-327. doi: 10.15414/jmbfs.2015.4.4.321-327
8. Ballal, S. A., Veiga, P., Fenn, K., Michaud, M., Kim, J. H., Gallini, C. A., et al. (2015). Host lysozyme-mediated lysis of Lactococcus lactis facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons. Proc. Natl. Acad. Sci. U.S.A. 112, 7803-7808. doi: 10.1073/pnas.1501897112
9. Benbouziane, B., Ribelles, P., Aubry, C., Martin, R., Kharrat, P., Riazi, A., et al. (2013). Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J. Biotechnol. 168, 120-129. doi: 10.1016/j.jbiotec.2013.04.019
10. Bermúdez-Humarán, L. G., Aubry, C., Motta, J.-P., Deraison, C., Steidler, L., Vergnolle, N., et al. (2013). Engineering lactococci and lactobacilli for human health. Curr. Opin. Microbiol. 16, 278-283. doi: 10.1016/j.mib.2013.06.002
11. Bermúdez-Humarán, L. G., Kharrat, P., Chatel, J. M., and Langella, P. (2011). Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb. Cell Fact. 10(Suppl. 1), S4. doi: 10.1186/1475-2859-10-S1-S4
12. Bermúdez-Humarán, L. G., Motta, J. P., Aubry, C., Kharrat, P., Rous-Martin, L., Sallenave, J. M., et al. (2015). Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microb. Cell Fact. 14, 26. doi: 10.1186/s12934-015-0198-4
13. Bermúdez-Humarán, L. G., Nouaille, S., Zilberfarb, V., Corthier, G., Gruss, A., Langella, P., et al. (2007). Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Appl. Environ. Microbiol. 73, 5300-5307. doi: 10.1128/AEM.00295-07
14. Bernet-Camard, M. F., Liévin, V., Brassart, D., Neeser, J. R., Servin, A. L., and Hudault, S. (1997). The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl. Environ. Microbiol. 63, 2747-2753.
15. Bolotin, A., Wincker, P., Mauger, S., Jaillon, O., Malarme, K., Weissenbach, J., et al. (2001). The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res. 11, 731-753. doi: 10.1101/gr.169701
16. Bowen, J. M., Stringer, A. M., Gibson, R. J., Yeoh, A. S. J., Hannam, S., and Keefe, D. M. (2007). VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol. Ther. 6, 1449-1454. doi: 10.4161/cbt.6.9.4622
17. Braat, H., Rottiers, P., and Hommes, D. W. (2006). A phase I Trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759. doi: 10.1016/j.cgh.2006.03.028
18. Caluwaerts, S., Vandenbroucke, K., Steidler, L., Neirynck, S., Vanhoenacker, P., Corveleyn, S., et al. (2010). AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 46, 564-570. doi: 10.1016/j.oraloncology.2010.04.008
19. Carlsson, A. H., Yakymenko, O., Olivier, I., Håkansson, F., Postma, E., Keita, ÅV., et al. (2013). Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. Scand. J. Gastroenterol. 48, 1136-1144. doi: 10.3109/00365521.2013.828773
20. Carr, F. J., Chill, D., and Maida, N. (2002). The lactic acid bacteria: a literature survey. Crit. Rev. Microbiol. 28, 281-370. doi: 10.1080/1040-840291046759
21. Carvalho, R. D. O., Breyner, N., Menezes-Garcia, Z., Rodrigues, N. M., Lemos, L., Maioli, T. U., et al. (2017). Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microb. Cell Fact. 16, 27. doi: 10.1186/s12934-017-0624-x
22. Carvalho, R. D. O., Morais, K., Pereira, V. B., Gomes-Santos, A. C., Luerce, T. D., de Azevedo, M. S. P., et al. (2016). Oral administration of Lactococcus lactis expressing recombinant 15-lipoxygenase-1 (15 LOX-1) modulates chemically induced colitis in mice. Med. Res. Arch. 4:1. doi: 10.18103/mra.v4i7.612
23. Chang, C., and Lin, H. (2016). Dysbiosis in gastrointestinal disorders. Best Pract. Res. Clin. Gastroenterol. 30, 3-15. doi: 10.1016/j.bpg.2016.02.001
24. Christa, L., Carnot, F., Simon, M. T., Levavasseur, F., Stinnakre, M. G., Lasserre, C., et al. (1996). HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells. Am. J. Physiol. 271, G993-G1002.
25. Christa, L., Simon, M. T., Brezault-bonnet, C., Bonte, E., Carnot, F., Zylberberg, H., et al. (1999). Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am. J. Pathol. 155, 1525-1533. doi: 10.1016/S0002-9440(10)65468-5
26. Clevers, H. C., and Bevins, C. L. (2013). Paneth cells: maestros of the small intestinal crypts. Annu. Rev. Physiol. 75, 289-311. doi: 10.1146/annurev-physiol-030212-183744
27. Cortes-Perez, N. G., Ah-Leung, S., Bermúdez-Humarán, L. G., Corthier, G., Wal, J.-M., Langella, P., et al. (2007). Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice. Clin. Vaccine Immunol. 14, 226-233. doi: 10.1128/CVI.00299-06
28. de Azevedo, M., Meijerink, M., Taverne, N., Pereira, V. B., LeBlanc, J. G., Azevedo, V., et al. (2015). Recombinant invasive Lactococcus lactis can transfer DNA vaccines either directly to dendritic cells or across an epithelial cell monolayer. Vaccine 33, 4807-4812. doi: 10.1016/j.vaccine.2015.07.077
29. de Koning, B. A., van Dieren, J. M., Lindenbergh-Kortleve, D. J., van der Sluis, M., Matsumoto, T., Yamaguchi, K., et al. (2006). Contributions of mucosal immune cells to methotrexate-induced mucositis. Int. Immunol. 18, 941-949. doi: 10.1093/intimm/dxl030
30. de Moreno de LeBlanc, A., del Carmen, S., Chatel, J.-M., Miyoshi, A., Azevedo, V., Langella, P., et al. (2015). Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models. Gastroenterol. Res. Pract. 2015:e146972. doi: 10.1155/2015/146972
31. de Vasconcelos Generoso, V., Rodrigues, N. M., Trindade, L. M., Paiva, N. C., Cardoso, V. N., Carneiro, C. M., et al. (2015). Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. Lipids Health Dis. 14:54. doi: 10.1186/s12944-015-0052-z
32. de Vos, W. M. (1999). Gene expression systems for lactic acid bacteria. Curr. Opin. Microbiol. 2, 289-295. doi: 10.1016/S1369-5274(99)80050-2
33. de Vos, W. M., and de Vos, E. A. (2012). Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr. Rev. 70, S45-S56. doi: 10.1111/j.1753-4887.2012.00505.x
34. Del Carmen, S., de Moreno de LeBlanc, A., Martin, R., Chain, F., Langella, P., Bermúdez-Humarán, L. G., et al. (2014). Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl. Environ. Microbiol. 80, 869-877. doi: 10.1128/AEM.03296-13
35. Derre, I., Rapoport, G., and Msadek, T. (1999). CtsR, a novel regulator of stress, and heat shock response, controls clp, and molecular chaperone gene expression in Gram-positive bactéria. Mol. Microbiol. 31, 117-131. doi: 10.1046/j.1365-2958.1999.01152.x
36. Eun, C. S., Kim, Y. S., Han, D. S., Choi, J. H., Lee, A. R., and Park, Y. K. (2011). Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. APMIS 119, 49-56. doi: 10.1111/j.1600-0463.2010.02691.x
37. Ewaschuk, J. B., Diaz, H., Meddings, L., Diederichs, B., Dmytrash, A., Backer, J., et al. (2008). Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am. J. Physiol. 295, G1025-G1034. doi: 10.1152/ajpgi.90227.2008
38. FAO/WHO (2002). "Guidelines for the evaluation of probiotics in food, " in Proceedings of the Joint FAO/WHO Working Group Meeting, London, ON.
39. Fedorak, R. N., Gangl, A., Elson, C. O., Rutgeerts, P., Schreiber, S., Wild, G., et al. (2000). Recombinant human interleukin 10 in the treatment of patients with mild tomoderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology 119, 1473-1482. doi: 10.1053/gast.2000.20229
40. Felis, G. E., and Dellaglio, F. (2007). Taxonomy of lactobacilli and bifidobacteria. Curr. Issues Intest. Microbiol 8, 44-61.
41. Gaudier, E., Michel, C., Segain, J.-P., Cherbut, C., and Hoebler, C. (2005). The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J. Nutr. 135, 2753-2761.
42. Guglielmetti, S., Taverniti, V., Minuzzo, M., Arioli, S., Stuknyte, M., Karp, M., et al. (2010). Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl. Environ. Microbiol. 76, 3948-3958. doi: 10.1128/AEM.00109-10
43. Han, W., Mercenier, A., Ait-Belgnaoui, A., Pavan, S., Lamine, F., van Swam, I. I., et al. (2006). Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm. Bowel Dis. 12, 1044-1052. doi: 10.1097/01.mib.0000235101.09231.9e
44. Harder, J., Meyer-Hoffert, U., Wehkamp, K., Schwichtenberg, L., and Schröder, J.-M. (2004). Differential gene induction of human β-defensins (hBD-1,-2,-3, and-4) in keratinocytes is inhibited by retinoic acid. J. Investig. Dermatol. 123, 522-529. doi: 10.1111/j.0022-202X.2004.23234.x
45. Henker, J., Laass, M., Blokhin, B. M., Bolbot, Y. K., Maydannik, V. G., Elze, M., et al. (2007). The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr. 166, 311-318. doi: 10.1007/s00431-007-0419-x
46. Hidalgo-Cantabrana, C., Nikolic, M., López, P., Suárez, A., Miljkovic, M., Kojic, M., et al. (2014). Exopolysaccharide-producing Bifidobacterium animalis subsp. lactis strains and their polymers elicit different responses on immune cells from blood and gut associated lymphoid tissue. Anaerobe 26, 24-30. doi: 10.1016/j.anaerobe.2014.01.003
47. Holvoet, S., Doucet-Ladevèze, R., Perrot, M., Barretto, C., Nutten, S., and Blanchard, C. (2016). Beneficial effect of Lactococcus lactis NCC 2287 in a murine model of eosinophilic esophagitis. Allergy 71, 1753-1761. doi: 10.1111/all.12951
48. Holzapfel, W. H., Haberer, P., Snel, J., Schillinger, U., and Huis in't Veld, J. H. (1998). Overview of gut flora and probiotics. Int. J. Food Microbiol. 41, 85-101. doi: 10.1016/S0168-1605(98)00044-0
49. Hong, J. P., Lee, S.-W., Song, S. Y., Ahn, S. D., Shin, S. S., Choi, E. K., et al. (2009). Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. Eur. J. Cancer Care 18, 636-641. doi: 10.1111/j.1365-2354.2008.00971.x
50. Hooper, L. V. E., and Macpherson, A. J. (2010). Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 10, 159-169. doi: 10.1038/nri2710
51. Hou, C. L., Zhang, J., Liu, X. T., Liu, H., Zeng, X. F., and Qiao, S. Y. (2014). Superoxide dismutase recombinant Lactobacillus fermentum ameliorates intestinal oxidative stress through inhibiting NF-κB activation in a trinitrobenzene sulphonic acid-induced colitis mouse model. J. Appl. Microbiol. 116, 1621-1631. doi: 10.1111/jam.12461
52. Iannitti, T., and Palmieri, B. (2010). Therapeutical use of probiotic formulations in clinical practice. Clin. Nutr. 29, 701-725. doi: 10.1016/j.clnu.2010.05.004
53. Izcue, A., Coombes, J. L., and Powrie, F. (2009). Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27, 313-338. doi: 10.1146/annurev.immunol.021908.132657
54. Johansson, M. E. V., Sjövall, H., and Hansson, G. C. (2013). The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 10, 352-361. doi: 10.1038/nrgastro.2013.35
55. Johnson, B. R., and Klaenhammer, T. R. (2014). Impact of genomics on the field of probiotic research: historical perspectives to modern paradigms. Antonie Van Leeuwenhoek 106, 141-156. doi: 10.1007/s10482-014-0171-y
56. Kashyap, D. R., Rompca, A., Gaballa, A., Helmann, J. D., Chan, J., Chang, C. J., et al. (2014). Peptidoglycan recognition proteins kill bacteria by inducing oxidative, thiol, and metal stress. PLoS Pathog. 10:e1004280. doi: 10.1371/journal.ppat.1004280
57. Kuipers, O. P., Beerthuyzen, M. M., Siezen, R. J., and De Vos, W. M. (1993). Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Eur. J. Biochem. 216, 281-291. doi: 10.1111/j.1432-1033.1993.tb18143.x
58. Langella, P., and Le Loir, Y. (1999). Heterologous protein secretion in Lactococcus lactis: a novel antigen delivery system. Braz. J. Med. Biol. Res. 32, 191-198. doi: 10.1590/S0100-879X1999000200007
59. Le Loir, Y., Azevedo, V., Oliveira, S. C., Freitas, D. A., Miyoshi, A., Bermúdez-Humarán, L. G., et al. (2005). Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb. Cell Fact. 4, 2.
60. Le Loir, Y., Gruss, A., Ehrlich, S. D., and Langella, P. (1994). Direct screening of recombinants in gram-positive bacteria using the secreted staphylococcal nuclease as a reporter. J. Bacteriol. 176, 5135-5139. doi: 10.1128/jb.176.16.5135-5139.1994
61. Lebeer, S., Vanderleyden, J., and De Keersmaecker, S. C. J. (2010). Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 8, 171-184. doi: 10.1038/nrmicro2297
62. LeBlanc, J. G., del Carmen, S., Miyoshi, A., Azevedo, V., Sesma, F., Langella, P., et al. (2011). Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J. Biotechnol. 151, 287-293. doi: 10.1016/j.jbiotec.2010.11.008
63. Lennard-Jones, J. E. (1989). Classification of inflammatory Bowel disease. Scand. J. Gastroenterol. 24, 2-6. doi: 10.3109/00365528909091339
64. Levine, M. M., and Dougan, G. (1998). Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375-1376. doi: 10.1016/S0140-6736(05)79439-3
65. Limaye, S. A., Haddad, R. I., Cilli, F., Sonis, S. T., Colevas, A. D., Brennan, M. T., et al. (2013). Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119, 4268-4276. doi: 10.1002/cncr.28365
66. Liu, W., Pang, H., Zhang, H., and Cai, Y. (2014). "Biodiversity of lactic acid bacteria, " in Lactic Acid Bacteria, eds H. Zhang and Y. Cai (Berlin: Springer), 103-203.
67. Ljungh, A., and Wadström, T. (2006). Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol. 7, 73-89.
68. Luerce, T. D., Gomes-Santos, A. C., Rocha, C. S., Moreira, T. G., Cruz, D. N., Lemos, L., et al. (2014). Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis. Gut Pathog. 6:33. doi: 10.1186/1757-4749-6-33
69. Lv, Y., Yang, X., Huo, Y., Tian, H., Li, S., Yin, Y., et al. (2012). Adenovirus-mediated hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein suppresses dextran sulfate sodium-induced acute ulcerative colitis in rats. Inflamm. Bowel Dis. 18, 1950-1960. doi: 10.1002/ibd.22887
70. Mack, D. R., Ahrne, S., Hyde, L., Wei, S., and Hollingsworth, M. A. (2003). Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52, 827-833. doi: 10.1136/gut.52.6.827
71. Mackowiak, P. A. (2013). Recycling metchnikoff: probiotics, the intestinal microbiome and the quest for long life. Front. Public Health 1:52. doi: 10.3389/fpubh.2013.00052
72. Majamaa, H., and Isolauri, E. (1997). Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol. 2, 179-185. doi: 10.1016/S0091-6749(97)70093-9
73. Malka, D., Vasseur, D., Bodeker, H., Ortiz, E. M., Dusetti, N. J., Verrando, P., et al. (2000). Tumor necrosis factor triggers antiapoptotic mechanisms in rat pancreatic cells through pancreatitis-associated protein I activation. Gastroenterology 119, 816-828. doi: 10.1053/gast.2000.16491
74. Mattar, A., Teitelbaum, D. H., Drongowski, R., Yongyi, F., Harmon, C., and Coran, A. (2002). Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int. 18, 586-590. doi: 10.1007/s00383-002-0855-7
75. Mercenier, A. (1999). "Lactic acid bacteria as live vaccines, " in Probiotics: A Critical Review, ed. G. Tannock (Wymondham: Horizon Scientific Press), 113-127.
76. Mierau, I., and Kleerebezem, M. (2005). 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol. 68, 705-717. doi: 10.1007/s00253-005-0107-6
77. Miyoshi, A., Bermúdez-Humarán, L., Azevedo, M. P. D., Langella, P., and Azevedo, V. (2010). "Lactic acid bacteria as live vectors: heterologous protein production and delivery systems, " in Biotechnology of Lactic Acid Bacteria Novel Applications, eds F. Mozzi, R. Raya, and G. Vignolo (Ames, IA: Blackwell Publishing), 9. doi: 10.1002/9780813820866.ch9
78. Miyoshi, A., Jamet, E., Commissaire, J., Renault, P., Langella, P., and Azevedo, V. (2004). A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol. Lett. 239, 205-212. doi: 10.1016/j.femsle.2004.08.018
79. Moal, V. L.-L., Sarrazin-Davila, L. E., and Servin, A. L. (2007). An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea. Pediatrics 120:e795-803. doi: 10.1542/peds.2006-2930
80. Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001
81. Nauta, A., van Sinderen, D., Karsens, H., Smit, E., Venema, G., and Kok, J. (1996). Inducible gene expression mediated by a repressor-operator system isolated from Lactococcus lactis bacteriophage r1t. Mol. Microbiol. 19, 1331-1341. doi: 10.1111/j.1365-2958.1996.tb02477.x
82. Neutra, M. R., and Kozlowski, P. A. (2006). Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148-158. doi: 10.1038/nri1777
83. Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., and Knight, S. C. (2009). Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. 15, 300-310. doi: 10.1002/ibd.20602
84. Nishitani, Y., Tanoue, T., Yamada, K., Ishida, T., Yoshida, M., Azuma, T., et al. (2009). Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int. Immunopharmacol. 9, 1444-1451. doi: 10.1016/j.intimp.2009.08.018
85. Nouaille, S., Ribeiro, L. A., Miyoshi, A., Pontes, D., Le Loir, Y., Oliveira, S. C., et al. (2003). Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res. 31, 102-111.
86. Ogawa, J., Matsumura, K., Kishino, S., Omura, Y., and Shimizu, S. (2001). Conjugated linoleic acid accumulation via 10-hydroxy-12-octadecaenoic acid during microaerobic transformation of linoleic acid by Lactobacillus acidophilus. Appl. Environ. Microbiol. 67, 1246-1252. doi: 10.1128/AEM.67.3.1246-1252.2001
87. Ohland, C. L., and MacNaughton, W. K. (2010). Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G807-G819. doi: 10.1152/ajpgi.00243.2009
88. O'Sullivan, D. J. (2001). Screening of intestinal microflora for effective probiotic bacteria. J. Agric. Food Chem. 49, 1751-1760. doi: 10.1021/jf0012244
89. Ouwehand, A. C., Salminen, S., and Isolauri, E. (2002). Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 82, 279-289. doi: 10.1023/A:1020620607611
90. Pedroso, S. H. S. P., Vieira, A. T., Bastos, R. W., Oliveira, J. S., Cartelle, C. T., Arantes, R. M. E., et al. (2015). Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 161, 1950-1960. doi: 10.1099/mic.0.000149
91. Pereira, V. B., Saraiva, T. D. L., Souza, B. M., Zurita-Turk, M., Azevedo, M. S. P., Castro, C. P. D., et al. (2014). Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+. Appl. Microbiol. Biotechnol. 99, 1817-1826. doi: 10.1007/s00253-014-6285-3
92. Peterson, L. W., and Artis, D. (2014). Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141-153. doi: 10.1038/nri3608
93. Piard, J. C., Hautefort, I., Fischetti, V. A., Ehrlich, S. D., Fons, M., and Gruss, A. (1997). Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J. Bacteriol. 179, 3068-3072. doi: 10.1128/jb.179.9.3068-3072.1997
94. Pontes, D. S., de Azevedo, M. S. P., Chatel, J.-M., Langella, P., Azevedo, V., and Miyoshi, A. (2011). Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Expr. Purif. 79, 165-175. doi: 10.1016/j.pep.2011.06.005
95. Prescott, S. L., and Björkstén, B. (2007). Probiotics for the prevention or treatment of allergic diseases. J. Allergy Clin. Immunol. 120, 255-262. doi: 10.1016/j.jaci.2007.04.027
96. Prisciandaro, L. D., Geier, M. S., Chua, A. E., Butler, R. N., Cummins, A. G., Sander, G. R., et al. (2012). Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. Support Care Cancer 20, 3205-3210. doi: 10.1007/s00520-012-1446-3
97. Qiao, H., Duffy, L. C., Griffiths, E., Dryja, D., Leavens, A., Rossman, J., et al. (2002). Immune responses in rhesus rotavirus-challenged Balb/c mice treated with bifidobacteria and prebiotic supplements. Pediatr. Res. 51, 750-755. doi: 10.1203/00006450-200206000-00015
98. Qiu, Z. B., Chen, J., Chen, J. J., Rong, L., Ding, W. Q., Yang, H. J., et al. (2013). Effect of recombinant Lactobacillus casei expressing interleukin-10 in dextran sulfate sodium-induced colitis mice. J. Dig. Dis. 14, 76-83. doi: 10.1111/1751-2980.12006
99. Quinto, E. J., Jiménez, P., Caro, I., Tejero, J., Mateo, J., and Girbés, T. (2014). Probiotic lactic acid bacteria: a review. Food Nutr. Sci. 5, 1765-1775. doi: 10.4236/fns.2014.518190
100. Ren, C., Zhang, Q., de Haan, B. J., Zhang, H., Faas, M. M., and de Vos, P. (2016). Identification of TLR2/TLR6 signalling lactic acid bacteria for supporting immune regulation. Sci. Rep. 6:34561. doi: 10.1038/srep34561
101. Rochat, T., Bermúdez-Humarán, L., Gratadoux, J. J., Fourage, C., Hoebler, C., Corthier, G., et al. (2007). Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb. Cell Fact. 6:22. doi: 10.1186/1475-2859-6-22
102. Rochat, T., Miyoshi, A., Gratadoux, J. J., Duwat, P., Sourice, S., Azevedo, V., et al. (2005). High-level resistance to oxidative stress in Lactococcus lactis conferred by Bacillus subtilis catalase KatE. Microbiology 151, 3011-3018. doi: 10.1099/mic.0.27861-0
103. Rottiers, P., Caluwaerts, S., Steidler, L., Vandenbroucke, K., Watkins, B., Sonis, S., et al. (2009). Effect of a mouth rinse formulation with human trefoil factor 1-secreting Lactococcus lactis in experimental oral mucositis in hamsters. J. Clin. Oncol. 27:e14570.
104. Ruiz, P., Alvarez-Martin, B., Mayo, C. G., de los Reyes-Gavilan, M., and Gueimonde, A. (2012). Controlled gene expression in bifidobacteria by use of a bile-responsive element. Appl. Environ. Microbiol. 78, 581-585. doi: 10.1128/AEM.06611-11
105. Salzman, N. H., Underwood, M. A., and Bevins, C. L. (2007). Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin. Immunol. 19, 70-83. doi: 10.1016/j.smim.2007.04.002
106. Santos Rocha, C., Gomes-Santos, A. C., Garcias Moreira, T., de Azevedo, M., Diniz Luerce, T., Mariadassou, M., et al. (2014). Local and systemic immune mechanisms underlying the anti-colitis effects of the dairy Bacterium Lactobacillus delbrueckii. PLoS ONE 9:e85923. doi: 10.1371/journal.pone.0085923
107. Schlee, M., Harder, J., Köten, B., Stange, E. F., Wehkamp, J., and Fellermann, K. (2008). Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2. Clin. Exp. Immunol. 151, 528-535. doi: 10.1111/j.1365-2249.2007.03587.x
108. Seo, E., Weibel, S., Wehkamp, J., and Oelschlaeger, T. A. (2012). Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. Int. J. Med. Microbiol. 302, 276-287. doi: 10.1016/j.ijmm.2012.05.002
109. Shortle, D. (1983). A genetic system for analysis of staphylococcal nuclease. Gene 22, 181-189. doi: 10.1016/0378-1119(83)90102-6
110. Shu, Q., and Gill, H. S. (2001). A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice. Med. Microbiol. Immunol. 189, 147-152. doi: 10.1007/s430-001-8021-9
111. Smith, C. L., Geier, M. S., Yazbeck, R., Torres, D. M., Butler, R. N., and Howarth, G. S. (2008). Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr. Cancer 60, 757-767. doi: 10.1080/01635580802192841
112. Soares, P. M. G., Mota, J. M. S. C., Souza, E. P., Justino, P. F. C., Franco, A. X., Cunha, F. Q., et al. (2013). Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine 61, 46-49. doi: 10.1016/j.cyto.2012.10.003
113. Southcott, E., Tooley, K. L., Howarth, G. S., Davidson, G. P., and Butler, R. N. (2008). Yoghurts containing probiotics reduce disruption of the small intestinal barrier in methotrexate-treated rats. Dig. Dis. Sci. 53, 1837-1841. doi: 10.1007/s10620-008-0275-1
114. Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., et al. (2000). Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355. doi: 10.1126/science.289.5483.1352
115. Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., et al. (2003). Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785-789. doi: 10.1038/nbt840
116. Stepaniuk, P., Bernstein, C. N., Targownik, L. E., and Singh, H. (2015). Characterization of inflammatory bowel disease in elderly patients: a review of epidemiology, current practices and outcomes of current management strategies. Can. J. Gastroenterol. Hepatol. 29, 327-333. doi: 10.1155/2015/136960
117. Stiles, M. E., and Holzapfel, W. H. (1997). Lactic acid bacteria of foods and their current taxonomy. Int. J. Food Microbiol. 36, 1-29. doi: 10.1016/S0168-1605(96)01233-0
118. Strober, W., Fuss, I., and Mannon, P. (2007). The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521. doi: 10.1172/JCI30587
119. Strukelj, B., Perse, M., Ravnikar, M., Lunder, M., Cerar, A., and Berlec, A. (2014). Improvement in treatment of experimental colitis in mice by using recombinant Lactococcus lactis with surface-displayed affibody against TNFa (THER4P.889). J. Immunol. 192, 137.1-137.1.
120. Thomas, H. (2016). IBD: Probiotics for IBD: a need for histamine? Nat. Rev. Gastroenterol. Hepatol. 13, 62-63. doi: 10.1038/nrgastro.2016.2
121. Tooley, K. L., Howarth, G. S., Lymn, K. A., Lawrence, A., and Butler, R. N. (2006). Oral ingestion of streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol. Ther. 5, 593-600. doi: 10.4161/cbt.5.6.2659
122. Tooley, K. L., Howarth, G. S., Lymn, K. A., Lawrence, A., and Butler, R. N. (2011). Oral ingestion of Streptococcus thermophilus does not affect mucositis severity or tumor progression in the tumor-bearing rat. Cancer Biol. Ther. 12, 131-138. doi: 10.4161/cbt.12.2.15720
123. van Asseldonk, M., Rutten, G., Oteman, M., Siezen, R. J., De Vos, W. M., and Simons, G. (1990). Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 95, 155-160. doi: 10.1016/0378-1119(90)90428-T
124. van Rooijen, R. J., Gasson, M. J., and de Vos, W. M. (1992). Characterization of the Lactococcus lactis lactose operon promoter: contribution of flanking sequences and LacR repressor to promoter activity. J. Bacteriol. 174, 2273-2280. doi: 10.1128/jb.174.7.2273-2280.1992
125. Vandermeulen, G., Marie, C., Scherman, D., and Préat, V. (2011). New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol. Ther. 19, 1942-1949. doi: 10.1038/mt.2011.182
126. Vangay, P., Ward, T., Gerber, J. S., and Knights, D. (2015). Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 17, 553-564. doi: 10.1016/j.chom.2015.04.006
127. Velasquez-Manoff, M. (2015). Gut microbiome: the peacekeepers. Nature 518, S3-S11. doi: 10.1038/518S3a
128. Vicariotto, F., Del Piano, M., Mogna, L., and Mogna, G. (2012). Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J. Clin. Gastroenterol. 46, S73-S80. doi: 10.1097/MCG.0b013e3182684d71
129. Vikhanski, L. (2016). Immunity: How Elie Metchnikoff Changed the Course of Modern Medicine. Chicago, IL: Chicago Review Press.
130. Villena, J., and Kitazawa, H. (2014). Modulation of intestinal TLR4-inflammatory signaling pathways by probiotic microorganisms: lessons learned from Lactobacillus jensenii TL2937. Front. Immunol. 4:512. doi: 10.3389/fimmu.2013.00512
131. Wang, M., Gao, Z., Zhang, Y., and Pan, L. (2016). Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. Appl. Microbiol. Biotechnol. 100, 5691-5701. doi: 10.1007/s00253-016-7557-x
132. Watterlot, L., Rochat, T., Sokol, H., Cherbuy, C., Bouloufa, I., Lefèvre, F., et al. (2010). Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int. J. Food Microbiol. 144, 35-41. doi: 10.1016/j.ijfoodmicro.2010.03.037
133. Wells, J. M., and Mercenier, A. (2008). Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6, 349-362. doi: 10.1038/nrmicro1840
134. Wells, J. M., Wilson, P. W., Norton, P. M., Gasson, M. J., and Le PageR, W. (1993). Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8, 1155-1162. doi: 10.1111/j.1365-2958.1993.tb01660.x
135. Westendorf, A. M., Gunzer, F., Deppenmeier, S., Tapadar, D., Hunger, J. K., Schmidt, M. A., et al. (2005). Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol. Med. Microbiol. 43, 373-384. doi: 10.1016/j.femsim.2004.10.023
136. Whitford, E. J., Cummins, A. G., Butler, R. N., Prisciandaro, L. D., Fauser, J. K., Yazbeck, R., et al. (2009). Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol. Ther. 8, 505-511. doi: 10.4161/cbt.8.6.7594
137. Wong, C. C. M., Zhang, L., Li, Z. J., Wu, W. K. K., Ren, S. X., Chen, Y. C., et al. (2012). Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis. J. Gastroenterol. Hepatol. 27, 1205-1212. doi: 10.1111/j.1440-1746.2012.07158.x
138. Yoshida, H., and Miyazaki, Y. (2008). Regulation of immune responses by interleukin-27. Immunol. Rev. 226, 234-247. doi: 10.1111/j.1600-065X.2008.00710.x